by promoting receptor-mediated homodimerization or, alternatively, by the formation of heterodimers with the orphan ErbB-2 through an as yet unknown mechanism. To investigate the selectivity in dimer formation by ligands, we have applied the phage display approach to obtain ligands with modified C-terminal residues that discriminate between ErbB-2 and ErbB-3 as dimerization partners. We used the epidermal growth factor/ transforming growth factor ␣ chimera T1E as the template molecule because it binds to ErbB-3 homodimers with low affinity and to ErbB-2/ErbB-3 heterodimers with high affinity. Many phage variants were selected with enhanced binding affinity for ErbB-3 homodimers, indicating that C-terminal residues contribute to the interaction with ErbB-3. These variants were also potent ligands for ErbB-2/ErbB-3 heterodimers despite negative selection for such heterodimers. In contrast, phage variants positively selected for binding to ErbB-2/ErbB-3 heterodimers but negatively selected for binding to ErbB-3 homodimers can be considered as "second best" ErbB-3 binders, which require ErbB-2 heterodimerization for stable complex formation. Our findings imply that epidermal growth factor-like ligands bind ErbB-3 through a multi-domain interaction involving at least both linear endings of the ligand. Apparently the ErbB-3 affinity of a ligand determines whether it can form only ErbB-2/ErbB-3 complexes or also ErbB-3 homodimers. Because no separate binding domain for ErbB-2 could be identified, our data support a model in which ErbB heterodimerization occurs through a receptor-mediated mechanism and not through bivalent ligands.
The recent determination of the crystal structure of the extracellular domain of ErbB-1 in complex with its ligands epidermal growth factor (EGF) 1 or transforming growth factor ␣ (TGF-␣) has provided evidence for the formation of homodimeric ErbB-1 complexes through a receptor-mediated dimerization mechanism (1, 2) . Ligand binding to both domains I and III of the extracellular domain of the receptor involves the transition of ErbB-1 from a "closed" to an "open" state, which then permits dimerization with another liganded ErbB-1 through interaction of domain II residues within these receptors. Most likely this mechanism can serve as a paradigm for homodimerization of other liganded ErbB receptors, such as ErbB-3 and ErbB-4. However, it is well established that EGFlike growth factors preferentially signal through heterodimers of their cognate receptor with the orphan ErbB-2. The mechanism by which EGF-like growth factors bind their receptors in heterodimeric receptor complexes remains an open question.
Dimerization of ligand-bound receptor tyrosine kinases is a mechanism that is thought to activate the intrinsic kinase domain followed by transphosphorylation and subsequent docking of cellular signal transducing proteins. As a consequence, ligand binding serves as a potential site for regulation of cell proliferation in diseases where ErbB receptors are overexpressed, as has been observed for ErbB-1 and ErbB-2 in multiple human cancers (3) . ErbB-2 has no known ligand, but by decelerating the ligand dissociation rate, it serves as a preferred dimerization partner for all other ErbB members (4 -6) . Heterodimer formation with ErbB-2 is especially important in the case of the ErbB-3, which together with ErbB-4 forms the natural receptor for the different neuregulins (NRGs). ErbB-3 contains a defective kinase and, hence, ErbB-3 homodimers are biologically inactive (7, 8) . The ErbB-2/ErbB-3 heterodimer, however, is the most prominent and strongest transforming signaling complex activated by NRG-1 (9 -12) and provides an attractive model system to study the mechanism of ligand-induced ErbB heterodimerization.
EGF-like growth factors share a structurally conserved EGF motif, characterized by three disulfide-bonded loops (the A-, B-, and C-loop), in addition to a linear N-terminal and C-terminal region. Structural and mutational analyses have shown that residues in the A-loop, C-loop, and C-terminal linear region of EGF and TGF-␣ primarily bind to domain III of ErbB-1 followed by an interaction of residues in their B-loop with domain I of the receptor (1, 2, (13) (14) (15) (16) . By contrast, NRG-1␤ has been shown to bind with high affinity to a proteolytic fragment of ErbB-3 containing only domain I (17) . Moreover, NRG binding to ErbB-1/ErbB-4 chimeras requires the presence of domain I of the latter receptor, suggesting that ligand binding to NRG receptors primarily involves interaction with domain I of the receptor (18) . Alanine scanning of NRG-1␤ revealed that hydrophobic and charged residues in the linear N-terminal region and the B-loop, which form a surface patch on one site of the triple ␤-sheet, are the major determinants in ErbB-3 binding (19, 20) . On the other hand, residues in the C-terminal region of NRG also may play a role in receptor binding, because the natural ␣ and ␤ isoforms of NRG-1 and NRG-2, which only vary * This work was supported by grants from the Dutch Cancer Society and the Netherlands Organization for Advancement of Research. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
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in sequences C-terminal of the fifth cysteine, strongly differ in their ability to bind and activate distinct ErbB combinations (21) (22) (23) (24) . Exchange studies between NRG-1␣ and NRG-1␤ show that particularly the linear C-terminal region determines the binding properties and mitogenic potential of these isoforms (25) . Therefore, it has been proposed that NRGs may have a bivalent character and interact with both ErbB-3 and ErbB-2 through separate binding sites (26) .
To evaluate the contribution of residues in the linear Cterminal region of EGF-like ligands for selective dimer formation, we applied the phage display technique to select ligands that discriminate between ErbB-2 and ErbB-3 as dimerization partners in ErbB-3 complexes. In earlier work we and others showed that EGF chimeras in which the linear N terminus was replaced by either NRG (biregulin) or TGF-␣ (T1E) residues gained high binding affinity to ErbB-2/ErbB-3 heterodimers, whereas they bound only weakly to ErbB-3 alone (27, 28) . Unlike NRG-1␤, both T1E and biregulin seem dependent on subsequent binding of ErbB-2 to stabilize their low affinity interaction with ErbB-3. In a previous study we could attribute the weak ErbB-3 interaction of the chimera T1E in part to the presence of sub-optimal sequences in the linear N terminus. Based on a phage display approach we enhanced the binding affinity for ErbB-3 relative to T1E by substitution of only two residues in EGF (D2W and S3 V/R) (29) . In the present study we have used the same approach to subject five residues in the linear C-terminal region of T1E for randomization and selection for altered receptor selectivity and affinity. The targeted residues in T1E correspond to the positions in the NRG isoforms that have been implicated in the differential activation of ErbB dimers. Here we show that T1E can be strongly optimized for binding to ErbB-3 by the current phage display approach, indicating that residues in the linear C-terminal tail contribute to the ability of ligands to bind ErbB-3 homodimers. Moreover, despite negative selection protocols we consistently observed a direct relation between the ability of T1E variants to bind ErbB-3 and their ability to induce ErbB-2/ErbB-3 heterodimers. Because no sequences selective for ErbB-2 heterodimerization could be identified, our findings support a model in which ErbB heterodimerization is driven by receptor-mediated and not by ligand-mediated interactions.
EXPERIMENTAL PROCEDURES
Construction of T1E Mutants-The construction of T1E has been described previously (28) . Residues in the linear C-terminal region after the sixth cysteine in pEZZ/Fx/T1E were replaced by the corresponding residues of TGF-␣ and NRG-1␤ by means of splice overlap extension polymerase chain reaction. The initial PCR fragments containing the complementary overhang sequences were made using pEZZ/Fx/T1E, pEZZ/Fx/TGF-␣, and the NRG-1␤ gene in pNRG8-g3 (a gift from Genentech Inc., San Francisco, CA) as templates. The fragment for the C-terminal region of the optimized NRG-1␤ (referred to as NRG-58 (30)) was constructed using oligonucleotide primers containing mutations encoding Asn-His and Met-Ile substitutions. Mutant gene products were subsequently introduced in the pEZZ vector using the BamHI/SalI sites and verified by automated cycle sequencing. Production, purification, and characterization of recombinant T1E mutants was essentially performed as previously described (28) .
Cell Lines-Interleukin-3-dependent murine 32D hematopoietic progenitor cells transfected with distinct human ErbB-encoding viral vectors or plasmids were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated fetal calf serum (Invitrogen), 0.25 ng/ml murine interleukin-3 (Promega, Madison, WI) and kept under continuous selection using 0.6 mg/ml G418 (Calbiochem) or 0.4 mg/ml hygromycin B (Sigma) (12) . The human mammary carcinoma cell line MDA-MB-453 was cultured in a 1:1 mixture of Dulbecco's modified Eagle's medium and Ham's F-12 medium supplemented with 10% fetal calf serum. Human embryonic kidney 293 cells were cultured in Dulbecco's modified Eagle's medium (Invitrogen) supplemented with 10% fetal calf serum.
Ligand Displacement Experiments-Recombinant human NRG-1␤ 176 -246 (R&D Systems, Minneapolis, MN) and T1E were radioiodinated using the Iodogen method (Pierce) according to the manufacturer's protocol for indirect labeling, resulting in a specific activity of 40 -80 Ci/g of protein.
Ligand displacement analyses on 32D cells were performed as described (28) . Construction of the Phage T1E 46 -50 Library-A phage library of T1E randomized by mutation to NNS codons (N ϭ G/T/A/C, S ϭ G/C) at positions Tyr-46, Arg-47, Asp-48, Leu-49, and Lys-50 (T1E numbering) was constructed by a PCR-based approach using fUSE5/T1E as template (29, 31) . The randomized region in the peptide growth factor was directly followed by the SfiI restriction site, thereby omitting the EGF residues Trp-51 to Arg-55. Because the randomized sequence was located in close proximity of the pIII fusion point, a flexible (Gly-Gly-GlySer) 2 linker sequence was introduced in the wild-type fUSE5 vector after the second SfiI site before to the gene encoding pIII. Wild-type fUSE5 contains an out-frame stuffer fragment between the SfiI sites, thereby eliminating background phage (32) . The PCR fragments encoding the randomized T1E gene were cloned into the fUSE5/linker phage vector using both SfiI sites. Ligation products were processed and electroporated into Escherichia coli TG-1 cells (Stratagene) for phage production. The number of independent transformants was determined by titration on tetracycline-containing plates to estimate the size of the library. Randomly picked clones from the library were analyzed by cycle sequencing (PerkinElmer Life Sciences) to confirm the diversity of codon use and the expected amino acid distribution. Phage preparations were carried out after standard polyethylene glycol 8000/NaCl precipitation procedures. Titers of filter-sterilized phages were estimated by both titration and spectrophotometric determination and expressed as titraing units (tu).
Preparation of ErbB-IgG Fusion Proteins-Gene constructs encoding the extracellular domain of human ErbB receptors were fused to the hinge and Fc regions of the human IgG1 heavy chain (referred to as ErbB-IgG (33)). Subconfluent HEK-293 cells were transfected with the expression vector pCDM7/IgB3 or a mixture of pCDM7/IgB3 with pCDM7/IgB2 using LipofectAMINE 2000 (Invitrogen) according to the manufacturer's protocol. Conditioned culture supernatants containing the soluble dimeric IgG fusion proteins were harvested 5-10 days after transfection and purified by affinity chromatography on a 1-ml Hi-trap protein A-Sepharose column (Amersham Biosciences). Purified IgG fusion proteins were eluted with 0.1 M citric acid, pH 4.2, into tubes containing 1 M Tris, pH 9.0. ErbB-IgG preparations were quantified by Fc-ELISA using human IgG as a standard, whereas the purity and presence of dimeric species was confirmed by SDS-polyacrylamide electrophoresis and immunoblotting with polyclonal antibodies directed against human Fc (Nordic, Tilburg, NL).
Phage Selection on ErbB-3-IgG Fusion Proteins-Nunc immunoabsorbant wells were precoated overnight at 4°C with 0.2 g of goat-antihuman Fc-specific IgG (Jackson Immunoresearch Laboratories, West Grove, PA) in 100 l of PBS (137 mM NaCl, 2.7 mM KCl, 1 mM Na 2 HPO 4 , 2 mM KH 2 PO 4 ). Wells were washed in PBS, 0.05% (v/v) Tween 20 (washing buffer) and blocked for 1 h in 0.2 ml of PBS, 0.2% (w/v) BSA (blocking buffer) at room temperature. Next, wells were coated with 100 ng of ErbB-3-IgG for 2 h in PBS, 0.2% BSA, 0.05% Tween 20 (binding buffer). Wells were rinsed twice and incubated with 1-3 ϫ 10 10 tu T1E 46 -50 phages in 0.1 ml of binding buffer. After incubation for 2 h, unbound phages were removed by rinsing 12 times with washing buffer. Bound phages were eluted by the addition of 0.1 ml of glycine buffer (50 mM glycine, 150 mM NaCl, pH 2.7) for 10 min, and the eluate was neutralized with 25 l of 1 M Tris/HCl, pH 8.0. The eluate was used for phage titration and infection of logarithmic cultures of TG-1 cells.
Whole Cell Phage Selection-Phage selections on MDA-MB-453 cells were carried out by incubation of 5-10 ϫ 10 6 cells in suspension with 1-3 ϫ 10 10 tu T1E 46 -50 phages in 3 ml of blocking buffer. In the case of ErbB-3-IgG depletion, the phages were subjected to ErbB-3-IgG as described above before cell selection. The unbound phages from ErbB-3-IgG wells were subsequently transferred to 12-ml Falcon tubes, diluted to 3 ml with binding buffer, and added to MDA-MB-453 cells. After incubation for 2 h on a rowing boat shaker, cells were rinsed 7 times in washing buffer by spinning for 4 min at 1000 rpm followed by resuspension and a final wash with PBS. Cells were transferred twice to clean tubes to remove phages non-specifically bound to the plastic. Specific elution was performed by competition with a 1:1 mixture of the anti-ErbB-2 monoclonal antibodies L26 and L96 (Neomarkers, Fremont, CA (34)) at 50 g/ml in binding buffer for 1 h at 4°C on a rowing boat shaker. Cells were spun, and the supernatant was collected as ErbB-2/ErbB-3 phage fraction. The remaining cell-bound phages were harvested by a 10-min incubation in 1 ml of acid elution buffer followed by neutralization upon adding 0.2 ml of 1 M Tris-HCl, pH 8.0. Cells were spun for 5 min at 1200 rpm, and the eluate was collected as ErbB-3 fraction. The distinct eluted fractions were used for phage titration and infection of logarithmic cultures of TG-1 cells.
Phage ELISA-Small scale phage preparations were used for the screening of individual clones in ELISA assays. PEG 8000 precipitates of culture broth of clones grown overnight in 2 ml 2ϫ TY (16 g/liter bacto-tryptone, 10 g/liter yeast, 5 g/liter NaCl) supplemented with 12.5 g/ml tetracycline in 12-well plates were resuspended in 100 l of PBS, typically resulting in phage titers of 1-5 ϫ 10 10 tu/ml. Whole cell ELISAs on 32D sublines in suspension were performed as described (29) . The procedure for ErbB-IgG ELISA was similar as described (20) , with the following modifications; homodimeric ErbB-3-IgG fusion proteins were coated at 50 ng/well, and heterodimeric ErbB-23-IgG fusions proteins were coated at 100 ng/well in 0.1 ml of binding buffer.
Cell Proliferation Assays-32D cells that coexpress ErbB-2 and ErbB-3 (D23 cells) were washed in RPMI 1640 medium to deprive them of interleukin-3. Subsequently cells were seeded into 96-well tissue culture plates at a density of 5.0 ϫ 10 4 cells/well in 0.1 ml of RPMI supplemented with 0.1% BSA together with serial dilutions of filtersterilized phages or recombinant growth factors. Cell survival was determined after 24 h of incubation at 37°C using the 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyl tetrazolium bromide (MTT) assay, as previously described (29) .
RESULTS

The Linear C-terminal Region of T1E Influences the ErbB-2/ErbB-3 Binding Efficiency-Previous work showed
that the chimeric EGF-like ligands biregulin and T1E bind only weakly to ErbB-3 due to sub-optimal sequences in the N-terminal linear region (26, 29) . The observed high affinity binding of T1E and biregulin for cells expressing both ErbB-2 and ErbB-3 thus appears to depend critically on additional stabilization of the complex by ErbB-2. The strong dependence on ErbB-2 as a dimerization partner makes this type of molecules a good model system for identifying residues that mediate the selective recruitment of ErbB-2 versus ErbB-3 as a dimerization partner.
In this study we have examined whether sequences in the C-terminal linear region of T1E play a direct role in the formation of ErbB-3 homodimeric and ErbB-2/ErbB-3 heterodimeric complexes, as suggested by a comparison of the different NRG isoforms. Thereto we initially exchanged the C-terminal linear tail of T1E, composed of EGF sequences, for the corresponding sequences of TGF-␣ (Glu-44 -Ala-50), NRG-1␤ (Gln-45-Ala-51) and an optimized NRG-1␤ mutant. This latter mutant has been obtained from a previous phage display study on NRG-1␤ by selection for high affinity binding to ErbB-3 ectodomains and contains the mutations N47H and M50I compared with the wild-type NRG-1␤ EGF domain (30) . The TGF-␣ C terminus was included because it shows the highest sequence similarity with optimized NRG-1␤ and because previous studies indicate that introduction of TGF-␣ C-terminal residues into NRG-1␣ strongly enhances binding affinity for ErbB-2/ErbB-3 heterodimers on SK-BR-3 cells (35) . The nomenclature used for the T1E mutants follows previously used conventions in which T1E6N is a chimera containing TGF-␣ sequences up to the first cysteine followed by EGF sequences up to the sixth cysteine and NRG-1␤ residues in the C-terminal tail (Fig. 1A) . All T1E mutants were expressed as recombinant peptides in E. coli, finally purified by reverse-phase HPLC and verified for the appropriate molecular weight by matrix-assisted laser desorption ionization time-of-flight spectroscopy analysis.
The biological activity of the various T1E mutants was assessed by competitive binding analysis on stable transfectants of 32D cells that express defined ErbB combinations (12) . opt (open diamonds). Unbound ligand was removed by sedimentation of the cells through a serum cushion, after which cell-bound radioactivity was determined. Results express the mean Ϯ S.E. of three independent experiments performed in duplicate.
tested to displace radiolabeled T1E from 32D cells coexpressing ErbB-2 and ErbB-3 (D23 cells). The IC 50 of both T1E6N and T1E6T (50 -60 ng/ml) was increased compared with T1E itself (6.7 ng/ml), whereas T1E6N opt bound D23 cells with enhanced affinity (3 ng/ml) comparable with wild-type NRG-1␤ (2 ng/ml). Similar differences were observed in the ability of these T1E mutants to stimulate proliferation of D23 cells and the neuregulin-responsive MCF-7 human breast cancer cells, indicating that their relative binding affinity corresponded to the ability to activate ErbB-2/ErbB-3 complexes (data not shown). Thus, changes in the C-terminal sequences of T1E strongly affect its ability to interact with ErbB-2/ErbB-3 heterodimers. Despite the fact that NRG-1␤ is the natural activator for ErbB-2/ErbB-3 heterodimers in vivo, its C-terminal sequences do not appear beneficial for the interaction with ErbB-2/ErbB-3 in a T1E environment. In this respect the EGF residues present in T1E appear more effective in stabilizing ErbB-2/ErbB-3 complexes than the corresponding NRG-1␤ and TGF-␣ sequences.
To further evaluate the role of the linear C terminus in binding to ErbB-3, the binding affinity of the T1E mutants was assessed by 125 I-labeled NRG-1␤ displacement on 32D cells solely expressing ErbB-3 receptors (D3 cells). In agreement with cross-linking analyses, we assume that NRG-1␤ is able to induce homodimeric ErbB-3 complexes in D3 cells (12, 26) . Fig.  1C shows that all T1E mutants have an affinity for ErbB-3 alone that is at least 50-fold lower than that of NRG-1␤. Compared with T1E, T1E6N opt shows increased binding affinity, whereas T1E6N and T1E6T have almost similar binding affinity. Thus, replacement of the C-terminal tail of T1E for NRG-1␤ sequences did not significantly improve the weak binding of T1E to the ErbB-3 receptor. By contrast, introduction of the C-terminal tail of the optimized NRG-1␤ variant increased the relative binding affinity of T1E for both homo-and heterodimeric ErbB-3 complexes, indicating these residues improve the recruitment of ErbB-2 and ErbB-3 independent of the context of the NRG molecule. Together these findings demonstrate that residues in the C-terminal region of T1E indeed contribute to the ligand preferences for distinct receptor complexes.
Design of the T1E 46 -50 Phage Library and Selection Strategy-To assess the precise contribution of individual residues in T1E to the recruitment of ErbB-2 or ErbB-3 into dimeric complexes, we randomly mutated five positions in the linear C terminus of T1E that correspond to the positions in the NRG isoforms implicated in differential ErbB binding using a phage display approach. By a combination of positive and negative selection strategies and specific elution methods we subsequently selected variants that discriminated between binding
Fig . 1A shows the sequence of the phage library of T1E variants. The Gln-45 residue next to Cys-44 is conserved between EGF and NRG-1␤, and therefore, the adjacent five residues (Tyr-46 -Lys-50) were targeted for mutation. Because the randomized area is localized in close proximity to the fusion point with the pIII minor coat protein, a flexible linker was introduced into the fUSE5 phage vector to minimize possible steric effects. The resulting phages each display 2-5 copies of the fusion proteins (32) . The completeness of the T1E
46 -50 phage library was estimated from the number of independent transformants yielding 1.45 ϫ10 7 , thereby covering 5 times the theoretical diversity of 3.1 ϫ10 6 possible different amino acid combinations. Sequence analysis of an aliquot of the library revealed no deviation from the theoretical amino acid distribution.
Sequences of T1E 46 -50 Clones Isolated for Preferential ErbB-3 Homodimer Formation-Phage T1E variants that preferentially bind to ErbB-3 homodimers but not ErbB-2/ErbB-3 heterodimers were isolated using alternating selection rounds on homodimeric ErbB-3-IgG fusion proteins and whole MDA-MB-453 cells. During the selection on cells the ErbB-2-dependent phage clones were depleted from the cell surface by competitive elution with anti-ErbB-2 antibodies that are known to impair ligand binding (34) . Subsequently the remaining phage clones bound to ErbB-3 receptors on the cell surface were harvested by acid elution. The alternation between exposure to soluble and cell-bound ErbB-3 receptors reduced nonspecific background binding of phages and excluded a possible selection advantage offered by the preformed dimeric ErbB-3-IgG compared with the monomeric cell-expressed receptors.
Individual phage clones were randomly picked after four selection rounds and subsequently analyzed for binding to ErbB-3 ectodomains in phage ELISA. Table I gives a survey of  the sequences of 16 T1E 46 -50 clones selected for preferential binding to ErbB-3 homodimers (ErbB-3 selectants) with their corresponding binding properties. Binding ability of the clones to ErbB-2/ErbB-3 heterodimers was determined in ELISAs on intact cells (D23 versus parental 32D cells) and on heterodimeric ErbB-23-IgG fusions. Because these heterodimeric IgG fusion proteins were generated by cotransfection of the expression vectors encoding the respective receptors, experiments were carried out on a mixture of ErbB-23-IgG het- erodimers and ErbB-2-IgG and ErbB-3-IgG homodimers. As a positive control EGF/WV phage was used, which is a previously characterized EGF variant with high affinity for ErbB-3 homodimers and ErbB-2/ErbB-3 heterodimers (29). Wild-type T1E phage and EGF phage were used as additional controls. Table I indicates that all ErbB-3 selectants displayed strong binding to ErbB-3-IgG, with concomitant strong binding capacity to both ErbB-23-IgG ectodomains and D23 cells. Thus, despite the negative selection for ErbB-2 dimers, the T1E clones selected by this approach had not lost their ability to bind to ErbB-2/ErbB-3 heterodimers. In other words, the ErbB-3 selectants are unable to discriminate between ErbB-2 and ErbB-3 as dimerization partners. The most striking result in the sequences obtained was the abundant selection of Asp-48 in 81% of the ErbB-3 selectants, which is the corresponding residue in both EGF and TGF-␣. Substitutes found on positions 46, 47, and 49 tended to be similar in character, being predominantly large and hydrophobic, although at position 46 a preference for Ile was observed (75%). At position 47 residues Tyr and Phe were found in more than half of the ErbB-3 selectants, indicating that aromatic side chains seem to be favored. The most frequently selected T1E 46 -50 clone, designated 3.1, contained IFDWA sequences (5/16 times). The overall consensus sequence for T1E 46 -50 ErbB-3 selectants, based on the frequency of occurrence of a certain (type of) amino acid detected at the respective position in Ն50% of all individual clones analyzed, was Ile-46 -aromatic-47-Asp-48 -apolar-49 -Xaa-50, in which Xaa represents any residue.
Sequences of T1E 46 -50 Clones Isolated for Selective ErbB-2/ ErbB-3 Heterodimer Formation-In an inverse strategy, phage T1E variants were isolated that selectively bound to ErbB-2/ ErbB-3 heterodimers but failed to bind to ErbB-3 homodimers. Thereto negative selection on homodimeric ErbB-3-IgG fusion proteins was performed before the selection on MDA-MB-453 cells. Ligands that ultimately depended on ErbB-2 for high affinity binding were eluted from the cell surface by treatment with ErbB-2 antibodies. Control cell panning confirmed the specific elution of wild-type T1E phages by this method (data not shown). After four rounds of selection, single clones were sequenced and analyzed for binding properties in ELISAs in a similar way as described above for the ErbB-3 selectants (Table  II) . All T1E clones selected for preferential ErbB-2/ErbB-3 binding (ErbB-23 selectants) were found to bind strongly to both D23 cells and ErbB-23-IgG ectodomains, confirming that selection had been achieved. When the ErbB-23 selectants were analyzed for their ability to bind to ErbB-3 homodimers, half of the clones lacked detectable binding for ErbB-3-IgG, similar to phage T1E (group 1), whereas the remaining were still able to bind with gradual affinity to ErbB-3 homodimers (group 2). Thus, only a fraction of the ErbB-23 selectants was able to discriminate against ErbB-3 as dimerization partner in the ErbB-3 complex.
When comparing the sequences of the two distinct groups of ErbB-23 selectants, both differences and similarities became apparent (Table II) . The consensus sequence of group 1 ErbB-23 selectants could be assigned as Tyr-46 -Leu-47-Xaa-48 -apolar-49 -Asp-50, whereas the consensus sequence of group 2 strongly resembled that of the ErbB-3 selectants in Table I . The diminished ability to bind to ErbB-3 homodimers of the group 1 clones correlated with a shift of the acidic Asp from position 48 (72% group 2) to position 50 (52% group 1). Predominantly large hydrophobic residues were found at positions 46, 47, and 49 in all ErbB-23 selectants, similarly as observed for the ErbB-3 selectants, although the exact nature of the side chains differed. Taken together, the overall consensus sequence of ErbB-23 selectants displays remarkable overlap with the consensus sequence for ErbB-3 selectants. Selected T1E 46 -50 Variants Display Gradual Differences in ErbB-3 Binding-To gain further insight into the relative contribution of specific amino acids to the ability of ligands to bind ErbB-3, we subjected a number of selected T1E 46 -50 phage variants to extended analysis using dose-response experiments. Based on the similarity and divergence from the consensus sequences, individual T1E selectants that harbor acidic Asp residues (at position 48 or 50 or at both positions) combined with distinct hydrophobic residues were chosen and produced as large scale cultures. Phage T1E served as a positive control for ErbB-2/ErbB-3 binding, and phage EGF/WV served as a positive control for ErbB-3 homodimer binding, whereas phage EGF was used as a negative control.
Although no absolute binding affinities could be determined by the used multivalent phage display system, the relative affinities could readily be compared between the distinct clones. All clones, whether they were isolated as ErbB-3 selectants ( Fig. 2A) or as ErbB-23 selectants (Fig. 2B ), invariably were found to bind with similar strong affinity to heterodimeric ErbB-23-IgG complexes. The binding of wild-type T1E to the ErbB-23-IgGs was relatively low in comparison to all other T1E variants and EGF/WV. This may be attributed to the flexible linker region that is present in the T1E 46 -50 phages but absent in the wild-type T1E phage. Conversely, the binding affinity of the various T1E 46 -50 clones to ErbB-3-IgGs showed strong variation between the clones, and in general the ErbB-3 selectants (Fig. 2C) were superior to the ErbB-23 selectants (Fig.  2D) . Interestingly, the ErbB-3 selectants with C-terminal sequences IFDWA, IADIQ, and YYDID showed significantly higher affinity for ErbB-3 than the positive control EGF/WV ( Fig. 2C) , indicating that C-terminal sequences strongly contribute to enhanced ErbB-3 affinity. When comparing the ErbB-23 selectants, a more or less gradual decrease in ErbB-3 binding affinity was observed in the order YYDID Ͼ YLEID ϭ YLQMN ϭ EGF/WV Ͼ YLDIS Ͼ YLTLD Ͼ T1E Ͼ YLSTD, and YLALH Ͼ Ͼ EGF (Fig. 2D) . Thus, acidic residues seem to contribute directly to the ErbB-3 binding affinity when located at position 48 and to a lesser extent when present at position 50. Moreover, acidic residues present at both positions seem beneficial for ErbB-3 binding, whereas the combination of Gln-48/ Asn-50 was also shown to be efficient. Apparently the depletion of the strongest ErbB-3 binding clones from the pool of ErbB-2/ErbB-3 selectants has resulted in the isolation of the second best ErbB-3 binding clones.
In addition, the abilities of the distinct T1E variants to activate ErbB-2/ErbB-3 heterodimers were assessed by measuring the interleukin-3-independent proliferation of D23 cells in an MTT assay. Fig. 3 shows that all T1E variants are equipotent to phage EGF/WV and superior to phage T1E itself in inducing proliferative responses in D23 cells, indicating that functional ErbB-2/ErbB-3 heterodimers are formed in response to all selectants. Thus, the ErbB-23 selectants only ineffectively bind to ErbB-3 homodimers, similar to T1E, but are still strong inducers of ErbB-2/ErbB-3 heterodimers. The ErbB-3 selectants effectively bind to ErbB-3 homodimers and ErbB-2/ ErbB-3 heterodimers, similar to EGF/WV, but this increased ErbB-3 affinity does not result in enhanced mitogenic potency for cells expressing ErbB-2 and ErbB-3. Therefore, it appears that a low threshold ErbB-3 binding is already sufficient for the efficient formation of ErbB-2/ErbB-3 heterodimers. DISCUSSION EGF-like ligands differ in their ability to recruit a dimerization partner for their cognate receptor, resulting in differential potency and mitogenic responses. This suggests that ligands contain specific residues that mediate interaction with distinct ErbB complexes, including heterodimers with the orphan ErbB-2. To investigate the selectivity in dimer formation by EGF-related ligands, we have applied the phage display approach to obtain ligands with modified C-terminal residues that have (i) altered selectivity and (ii) enhanced binding affinity. Our findings indicate that EGF-like growth factors contain multiple, independent binding domains for ErbB-3, one of which is located in the C-terminal tail. However, no separate binding domain for ErbB-2 could be identified in this region. Instead, ligand-induced ErbB-2/ErbB-3 heterodimerization appears to occur as a consequence of a low affinity interaction with ErbB-3 and subsequent stabilization by ErbB-2.
To address the issue of dimer selectivity, distinct combinations of positive and negative selection strategies were applied to isolate ligands that were able to discriminate between ErbB-2 and ErbB-3 in complex formation with ErbB-3. Two of our present observations argue against the hypothesis that the selectivity in recruitment of the dimerization partner is mediated by sequences in the linear C-terminal tail of ligands. First, none of the ErbB-3 selectants had impaired ability to form ErbB-2/ErbB-3 heterodimers despite the negative selection for T1E variants that depended on ErbB-2 dimerization for binding. The most likely explanation is that the linear C-terminal region is not directly involved in the recruitment of ErbB-2 as dimerization partner either because ligands do not harbor a separate ErbB-2 binding site or because such a site is located in a different region of the ligand. Hence, our data do not favor a model in which the linear C-terminal tail harbors a secondary binding site for ErbB-2, as previously proposed in ligand bivalence models (26, 36) .
Secondly, the incomplete discrimination against ErbB-3 homodimer formation observed for the ErbB-23 selectants might indicate that ligands require only a low level of ErbB-3 binding affinity to allow the efficient formation of ErbB-2/ErbB-3 heterodimers. These ligands can thus be considered as the "second best" ErbB-3 binders. Moreover, the observation that ligand variants positively selected for ErbB-3 binding but negatively for ErbB-2/ErbB-3 binding are still potent activators of heterodimers also strongly indicates that binding to ErbB-3 is sufficient for heterodimer formation. It thus appears that the relative binding affinity to ErbB-3 is indicative for the binding behavior of ligands to dimeric complexes, such that low affinity binders only interact with ErbB-2/ErbB-3 heterodimers, whereas high affinity binders can additionally form ErbB-3 homodimers. Our present observations argue for a separate ErbB-3 binding site located in the linear C-terminal tail of EGF-like ligands. Previous mutagenesis studies have assigned several non-continuous hydrophobic and charged residues in the triple ␤-sheet formed by the linear N-terminal region and the B-loop region of NRG-1 as the major determinants for ErbB-3 binding (19, 20, 27) . It cannot, however, be excluded that additional residues in the ligand may contribute to receptor interaction. For instance, residues in the ␤-turn in the A-loop of NRG-1 were also susceptible to Ala mutation, although this might be attributed to structural disturbance as well (20) . The crucial importance of N-terminal residues was further emphasized by two phage display studies, revealing the strong requirement for aromaticity (His or Trp) combined with aliphatic or basic side chains for ErbB-3 interaction (29, 30) . Here we show that optimized sequences in the C-terminal linear region also directly contribute to the ability of T1E ligands to interact with ErbB-3 and that they can compensate for the presence of suboptimal residues in the linear N terminus of T1E. Notably, the T1E 46 -50 variants selected for preferential binding to ErbB-3 homodimers displayed even stronger binding to ErbB-3-IgG than the EGF/W2V3 mutant (Fig. 2C) . Thus, although residues in the N terminus and B-loop appear to confer specificity to ErbB-3 binding, residues in the linear C-terminal tail may further enhance receptor affinity, in line with the differential ErbB-3 binding abilities of the distinct NRG-1 isoforms. This suggests that both linear regions of the ligand participate independently in receptor binding such that ligand binding to ErbB-3 occurs through a multidomain receptor interaction.
The C-terminal sequence requirements for ErbB-3 binding can be deduced from a comparison of the consensus sequences of the selected high and low affinity ErbB-3 binding variants. Large hydrophobic residues are preferred at positions 46, 47, and 49 in all selected T1E 46 -50 variants, whereas methionine was alternatively allowed at position 49. In particular Ile-46 contributes to enhanced ErbB-3 binding affinity. In addition, the presence of an acidic residue facilitates specific binding to ErbB-3, preferentially located at position 48 (for strong ErbB-3 binding) or, alternatively, at position 50 (for weak ErbB-3 binding). Because a combination of the polar residues Gln-48 and Asn-50 also proved sufficient (Fig. 2D) , we propose that these two side chains are involved in hydrogen bonding. Interestingly, in the structure of receptor-bound TGF-␣ several Cterminal residues interact with both domains I and III, among which is Asp-47 (1). It has been suggested that these residues determine the final position of the two ligand binding domains in the complex and thereby influence the stability of the dimer. It is tempting to speculate that in the T1E selectants Asp-48 may serve a similar function when binding to ErbB-3. Furthermore, all T1E variants selected for ErbB-3 binding maintained their ability to bind to ErbB-1 expressed on 32D cells and ErbB-1-IgG ectodomains, indicating that the requirements in the C-terminal tail for ErbB-1 and ErbB-3 interaction may partly overlap. 2 This observation is remarkable since the majority of selected clones lacked a Leu or Ile at position 49 in T1E (Leu-47 in EGF), which is strictly conserved among ErbB-1 ligands and known to be highly sensitive to site-directed mutagenesis (13, 14) .
Comparing the consensus sequence of the ErbB-3 selectants with that of the natural ErbB-3 ligands, one can conclude that the EGF linear C-terminal region comprising Tyr-46 -Asp-48 -Leu-49 contributes positively to the interaction with ErbB-3. The finding that T1E effectively forms ErbB-2/ErbB-3 heterodimers but not ErbB-3 homodimers can thus not be attributed to inappropriate C-terminal sequences, as previously thought. Rather, it reflects the presence of suboptimal residues in both its N-terminal and C-terminal region (29) . The observation that introduction of the NRG-1␤ C terminus into T1E did not increase the ErbB-3 binding affinity can be explained by the presence of only two of four required determinants, Tyr-47 and Met-49, with Met being a less-favored residue. In agreement, mutation of these two residues into alanine was found to reduce the ErbB-3 binding affinity of NRG-1␤ (20) . Apparently, natural ligands are not necessarily optimized for high affinity to their receptors, which is also indicated by the increase in ErbB-3 binding affinity of optimized NRG-1␤ variants (30) . Their affinity enhancement was mostly attributed to the Met to Ile substitution in the C-terminal tail, as also shown by the T1E6N opt mutant in our study. Interestingly, despite the abundant occurrence of Asp residues in the T1E variants optimized for ErbB-3 binding, acidic residues were not observed in optimized NRG-1␤ variants, which may be attributed to differences in the structural environment of T1E and NRG-1␤ (30) . We have recently solved the three-dimensional structure of T1E, 3 but because that of the NRG-1␤ isoform is unknown, a direct comparison is impossible.
Our results imply that specific residues in the C-terminal tail of EGF-related ligands are involved in direct interaction with ErbB-3 but not ErbB-2. This makes it unlikely that the formation of heterodimeric ErbB complexes is driven through bivalent binding of ligands to two different ErbB molecules. Instead, our findings support a receptor-mediated dimerization mechanism, in which ligand binding to ErbB-3 determines the formation of both ErbB-3 homodimers and ErbB-2/ErbB-3 heterodimers (Fig. 4) . In a variant of this model, it has been proposed that ligands only induce ErbB-3 homodimers, which may subsequently stabilize two ErbB-2 molecules into a tetrameric complex (37) (38) (39) (40) . Based on the analogy of the crystal structures of ErbB-1 and ErbB-3, it is most likely that homodimeric ErbB-3 complexes are formed through a conformation-induced mechanism with a 2:2 stoichiometry (1, 2, 41). In this scenario the ligand would bind domain I of ErbB-3 through the linear N-terminal and B-loop regions, whereas its C-terminal residues would interact with receptor domain III. In the conformation-induced model, selectivity between the formation of inactive ErbB-3 homodimers and active ErbB-2/ErbB-3 het- erodimers will be achieved through the intrinsic property of a ligand to bind ErbB-3 (Fig. 4) . Ligands with high affinity for domain I and/or III of ErbB-3, including NRG-1␤ and some of the ErbB-3 variants selected here, have a high potency to bring ErbB-3 into the open dimerization state and will, thus, induce both ErbB-3 homodimers and ErbB-2/ErbB-3 heterodimers. Ligands with relatively low affinity for ErbB-3 due to suboptimal interaction with domain I or III, such as T1E and NRG-1␣, have only a low potency to induce ErbB-3 into the open state, and only in the case the liganded ErbB-3 is complexed by ErbB-2 is a stable complex formed. This model presumes that the dimerization site of ErbB-2 is maintained constitutively in the open configuration, as an explanation for the preferential heterodimerization with ErbB-2. From an evolutionary point of view this would be a sensible mechanism to enhance the formation of active ErbB-2/ErbB-3 complexes and to avoid biologically inactive ErbB-3 homodimers. In this respect NRG-1␤ would be the optimal natural ligand if ErbB-2 is present in excess over ErbB-3, whereas the low affinity NRG-1␣ isoform would be more effective under conditions that ErbB-3 is present in excess over ErbB-2 (21, 24) . A switch in isoform production thus offers the cell a subtle method of control over cellular functions.
